India and Suriname MoU for Regulation Of Medical Products
Agreements
4 min read
The Union Cabinet was apprised of the Memorandum of Understanding signed between the Central Drugs Standard Control Organization (CDSCO) of the Ministry of Health and Family Welfare and the Ministry of Health of Suriname in the area of medical product regulation.
The agreement was signed on June 4, 2023 during the visit of President of India Draupadi Murmu to Suriname.
She was awarded the highest civilian award, the Grand Order of the Chain of the Yellow Star, during the visit of President Draupadi Murmu to Suriname. Became the first Indian to receive this honour from Suriname. She was presented with the award by Chandrikaprasad Santokhi, the President of the Republic of Suriname.
-
The objective of this MoU is to facilitate constructive dialogue on laws and regulations relating to medical products as well as other important matters.
-
This MoU provides for establishing a framework for fruitful cooperation and exchange of information between CDSCO and the Government of the Republic of Suriname in matters relating to the regulation of medical products consistent with their international responsibilities.
Key areas of cooperation-
-
To promote understanding between the Parties of each other's regulatory framework, requirements and procedures and facilitate future regulatory strengthening initiatives for both Parties.
-
Exchange of information and cooperation on Good Laboratory Practices (GLP), Good Clinical Practice (GCP), Good Manufacturing Practice (GMP) and Good Pharma-covigilance Practice (GPVP).
-
Recognition of Indian Pharmacopoeia.
-
Exchange of safety information, including pharma-covigilance and adverse events, where there is a specific safety concern relating to the other side. This includes safety concerns related to drugs and medical devices.
-
Scientific participation in scientific and practical conferences, symposia, seminars and forums organised by the parties concerned.
-
Capacity building in mutually agreed areas.
-
Coordination on the international stage.
Benefits of this MoU:
-
The MoU will facilitate export of medical products thereby earning foreign exchange.
-
The harmonisation of regulatory practices would help in increasing the export of drugs from India and could result in better employment opportunities for educated professionals in the pharma sector.
-
The MoU signed between the regulatory authorities of the two countries will facilitate better understanding of regulation of medical products with respect to pharmaceuticals including raw materials, biological products, medical devices and cosmetic products for pharmaceutical use.
-
The MoU will promote information exchange and cooperation in areas involving medical products and important administrative and regulatory matters within the jurisdiction of the parties concerned.
Suriname:
-
Capital: Paramaribo
-
Currency: Surinamese dollar (SRD)
-
President: Chandrikaprasad Santokhi
